天士力：席凯辞去公司副总经理职务

Group 1 - The core point of the article is the resignation of Mr. Xi Kai, the Deputy General Manager of Tian Shi Li, due to work adjustments, while he will continue to serve as an employee director [1] - For the fiscal year 2024, Tian Shi Li's revenue composition is as follows: Traditional Chinese Medicine accounts for 70.89%, Chemical Preparations 15.38%, Pharmaceutical Commerce 10.53%, Biological Drugs 2.25%, and Chemical Raw Materials 0.61% [1] - As of the report date, Tian Shi Li has a market capitalization of 22.7 billion yuan [1] Group 2 - The article also highlights a significant issue in the pharmaceutical industry regarding the abuse of Pregabalin, marking the first reported case of addiction in China, raising concerns about the accessibility of prescription drugs without proper medical records [1]